Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 206

Results For "INST"

3139 News Found

Krsnaa Diagnostics bags large tender in Maharashtra
Clinical Trials | July 26, 2022

Krsnaa Diagnostics bags large tender in Maharashtra

The tenure of contract will be upto 10 years from date of signing the contract/installation.


Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr
News | July 26, 2022

Astec LifeSciences Q1 FY2023 consolidated PAT drops to Rs. 11.39 Cr

The company has reported total income of Rs. 186.97 crores during the period ended June 30, 2022.


Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr
News | July 26, 2022

Vikas Lifecare consolidated Q1FY23 PAT at Rs. 2.59 Cr

The company has reported total income of Rs. 94.30 crores during the period ended June 30, 2022.


GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr
News | July 26, 2022

GlaxoSmithKline Pharmaceuticals Q1FY23 consolidated PAT at Rs. 119.28 Cr

GlaxoSmithKline Pharmaceuticals has reported total income of Rs. 772.71 crores during the period ended June 30, 2022


Healthcare Triangle launches in Singapore; Leveraging AI and cloud in Asia Pacific Markets
Digitisation | July 26, 2022

Healthcare Triangle launches in Singapore; Leveraging AI and cloud in Asia Pacific Markets

The region's digital health market, valued at USD 40.3 billion in 2021, is expected to expand to USD 326.7 billion by 2030 at a CAGR of 26.5 per cent.


Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr
News | July 26, 2022

Suven Life Sciences posts Q1FY23 consolidated loss at Rs. 16.32 Cr

Suven Life Sciences has reported total income of Rs. 3.97 crores during the period ended June 30, 2022


Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr
News | July 26, 2022

Sanofi India Q2 CY2022 PAT drops 49.5% to Rs. 120.4 Cr

Sanofi India has reported total income of Rs. 715 crores during the period ended June 30, 2022.


Funds for R&D in drug discovery and manufacturing :PIB
Policy | July 26, 2022

Funds for R&D in drug discovery and manufacturing :PIB

An outlay of Rs. 1,500 crore has been approved for strengthening/ up-gradation of these NIPERs for the period 2021-22 to 2025-26.


Import of Medical Devices Up by Record 41% in FY22: AiMeD
News | July 24, 2022

Import of Medical Devices Up by Record 41% in FY22: AiMeD

India imported medical devices worth Rs. 63,200 crore in 2021-22, up 41% from Rs. 44,708 crore in 2020-21


Syngene reports revenue from operations up 8% in Q1 FY 23
News | July 21, 2022

Syngene reports revenue from operations up 8% in Q1 FY 23

Company raises the annual revenue guidance from mid-teens to high teens